Cargando…

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria

Central and Eastern European countries (CEEC) have among the highest rates of increase in healthcare expenditure. External reference pricing, generics and biologics price capping, regressive scale for price setting, health technology assessment (HTA), and positive drug lists for reimbursed medicines...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitkova, Zornitsa, Dimitrova, Maria, Doneva, Miglena, Tachkov, Konstantin, Kamusheva, Maria, Marinov, Lyubomir, Gerasimov, Nikolay, Tcharaktchiev, Dimitar, Petrova, Guenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9691655/ https://www.ncbi.nlm.nih.gov/pubmed/36438231 http://dx.doi.org/10.3389/fpubh.2022.1011928

Ejemplares similares

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2019)

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Medication Adherence among Patients with Diabetes Mellitus and Its Related Factors—A Real-World Pilot Study in Bulgaria
por: Dinkova, Rayana, et al.
Publicado: (2023)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Analysis of the Household and Health Care System Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Availability and reimbursement of biological products for severe asthma in Bulgaria
por: Milushewa, Petya, et al.
Publicado: (2020)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects
por: Mitkova, Zornitsa, et al.
Publicado: (2019)

Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
por: Karanyotova, Stephanie, et al.
Publicado: (2023)

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment
por: Petrova, Guenka, et al.
Publicado: (2014)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
por: Tkachova, Oksana, et al.
Publicado: (2019)

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2023)

Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
por: Dimitrova, Maria, et al.
Publicado: (2014)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria
por: Dimitrova, Maria, et al.
Publicado: (2017)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
por: Kamusheva, Maria, et al.
Publicado: (2021)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
por: Tachkov, Konstantin, et al.
Publicado: (2022)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
por: Dimitrova, Maria, et al.
Publicado: (2022)

Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy
por: Petrova, Guenka, et al.
Publicado: (2017)

Comparison of Cardiovascular Medicines Prices in Four European Countries
por: Mitkova, Zornitsa, et al.
Publicado: (2020)

Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria
por: Turcu-Stiolica, Adina, et al.
Publicado: (2021)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

ISO 9001 certification for hospitals in Bulgaria: does it help service?
por: Stoimenova, Assena, et al.
Publicado: (2014)

Cost of outpatient hypertension pharmacotherapy: comparative study between Bulgaria and Serbia
por: Ivanova, Anna, et al.
Publicado: (2009)

Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making
por: Németh, Bertalan, et al.
Publicado: (2023)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Health spending and ability to pay: Business, individuals, and government
por: Levit, Katharine R., et al.
Publicado: (1989)

Procedure for spending and internally accounting the money of the 1960 budget
por: Reich, K H
Publicado: (1960)

Procedure for spending and internally accounting the money of the 1960 budget
por: Reich, K H
Publicado: (1960)

Prospects of Risk-Sharing Agreements for Innovative Therapies in a Context of Deficit Spending in Bulgaria
por: Iskrov, Georgi, et al.
Publicado: (2015)

Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases—STOPP/START-based study
por: Krustev, Tzvetan, et al.
Publicado: (2022)

Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study
por: Stoeva, Vera, et al.
Publicado: (2023)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6gpebmb55mve0ai064trntjti8